Transcript Highlights:

• You imagine FDA lining up to sue these people?
• bad position, and you're putting the physicians and nurse practitioners in a bad position because the FDA
• that were made about ivermectin: our bill analysis very well pointed this out, that when it is used at FDA-approved
• they're not viewing that to be out of step with what's appropriate if it's done in accordance with FDA
• Now, our bill does allow it to be behind... ...what's appropriate if it's done in accordance with FDA

Summary: The Senate began with opening prayer, the Pledge of Allegiance, and recognitions, including the doctor of the day and a lighthearted “Cannoli Day” introduction. The chamber then held an extended farewell celebration for Senator Joe Gruters, with numerous senators, colleagues, and family members praising his loyalty, political skill, family focus, and service in the Legislature and Republican Party. Gruters was presented with a commemorative gift recognizing his work on a 2019 public-safety and immigration bill that prohibited sanctuary cities and required local cooperation with federal immigration enforcement. The Senate adopted a motion to spread Gruters’s remarks upon the journal and then recessed briefly. After recess, the Senate returned to regular business and took up third-reading bills. Committee Substitute for Committee Substitute for Committee Substitute for Senate Bill 354, relating to blue ribbon projects, was temporarily postponed. The chamber then considered Committee Substitute for Committee Substitute for Senate Bill 1758, relating to public assistance, with Senator Gates explaining that it contained five reforms to the public assistance system discussed earlier in session. During debate on SB 1758, Senator Berman opposed the bill, saying he could not support it in its current form because he believed the Medicaid-related provisions would create a coverage cliff after the one-year transition period and could leave people without care while increasing costs to hospitals and taxpayers. He also said SNAP error reduction should be a priority, but argued the state should focus on fixing administrative errors and fraud rather than imposing a work requirement whose costs and effects were uncertain.

Transcript Highlights:

• You imagine FDA lining up to sue these people?
• bad position, and you're putting the physicians and nurse practitioners in a bad position because the FDA
• that were made about ivermectin: our bill analysis very well pointed this out, that when it is used at FDA-approved
• they’re not viewing that to be out of step with what’s appropriate if it’s done in accordance with FDA
• Now, our bill does allow it to be behind... ...what’s appropriate if it’s done in accordance with FDA

Summary: The Senate opened with prayer, the Pledge of Allegiance, and several introductions, then devoted most of the first part of the meeting to a farewell-style recognition of Senator Joe Gruters. Senators from both parties offered extended remarks praising his loyalty, political instincts, family involvement, and work as a legislator and as incoming Republican National Committee chair. Gruters responded with remarks about his background, including overcoming a childhood speech impediment, his service in the Legislature, and major policy efforts he highlighted such as alimony reform and the undergrounding of utilities. A ceremonial gift was presented to him recognizing his work on a 2019 public-safety/immigration bill, and the Senate adopted a motion to spread his remarks upon the journal before recessing briefly. After the recess, the Senate returned to regular business. No committee reports, governor’s messages, House messages, or reconsideration matters were reported. The chamber then moved to third reading and temporarily postponed CS/CS/CS/SB 354, relating to blue ribbon projects. The next bill, CS/CS/SB 1758, relating to public assistance, was taken up, and Senator Gaetz explained that it contained five reforms to the public assistance system previously discussed by the Senate. Debate was about to continue when the transcript ended.

Transcript Highlights:

• amendment defines therapeutic equivalent and clarifies that health plans are not required to cover every FDA-approved
• amendment defines therapeutic equivalent and clarifies that health plans are not required to cover every FDA-approved

Summary: The Senate received a large number of House communications and committee reports, including several nominations and many bills and resolutions returned from House committees or passed by the House. Committee reports covered a wide range of topics, including education, health, judiciary, finance, housing, transportation, emergency management, and business/technology. The Senate also assigned several measures to committees for further consideration and noted upcoming committee meetings. The chamber confirmed three nominations by roll call: Michael T. Scuse to the Delaware Thoroughbred Racing Commission, J. Eric Firewold to the University of Delaware Board of Trustees, and Joan F. Coker to the University of Delaware Board of Trustees. The Senate also passed Consent Calendar 66, which included Senate Concurrent Resolution 223 on DIA broadcast access for playoff and championship games and House Concurrent Resolution 149 designating June 12, 2026, as Loving Day in Delaware. Members discussed Loving Day and the importance of recognizing interracial marriage rights, with Senator Huxstable, Senator Buckson, and Senator Townsend offering remarks. On the floor, the Senate passed House Bill 141, requiring a firearm responsibilities notice for gun purchasers, after debate over gun safety and industry burden; House Substitute 1 for House Bill 200, as amended, expanding insurance coverage for HIV prevention medications PrEP and PEP; House Bill 426, modernizing municipal street-aid reporting; and Senate Resolution 21, directing a study of portable solar generation devices and related safety and utility issues. The Senate also passed Consent Agenda O, a large package of bills covering topics such as money transmission and stablecoins, nursing advancement, pilot licenses, commerce and trade, subaqueous lands, driver’s license loss due to medical issues, residential speed limits, electronic bidding, family court jurisdiction, agency regulations, technical corrections to multiple local charters, and other measures. The Senate then recessed until June 25, 2026.

Transcript Highlights:

• On average, it is a two- to three-year delay for approval compared to approval by the FDA, if that is
• AVERAGE IT IS A 2 TO 3 YEAR DELAY FOR AN   491 APPROVAL THAN IT IS TO HAVE APPROVAL TO THE FDA

Summary: The committee first took up CS/House Bill 981, which would restore the Ocklawaha River and related natural resources. Supporters, including environmental groups, Save the Manatee Club, business owners, and Reunite the Rivers advocates, argued the bill would improve manatee habitat, fish passage, flood protection, tourism, and long-term economic returns while reducing dam maintenance costs. Opponents and skeptics focused on concerns about water quality, nutrient loading in the St. Johns River, loss of the Rodman Reservoir’s habitat and water-supply value, and potential ecological and economic harms. Members in debate largely supported the restoration effort, and the bill was reported favorably on a unanimous vote. The committee then heard HB 697, the PRICE Act, which would use international reference pricing to set a drug cost benchmark, address pharmacy benefit manager practices, and require health plans to keep drug prices stable for the year. The sponsor said the bill would lower costs and improve access, especially for uninsured Floridians. Supporters, including independent pharmacists, argued PBMs are squeezing pharmacies and that the bill could help lower prices. Opponents from BioFlorida and PhRMA warned the proposal could disrupt the national drug supply chain, fail to pass savings to patients, and lead to shortages, reduced access, and less innovation. After debate, the bill passed favorably, with Rep. Chambliss voting no. The committee also considered CS/HB 1081, which was amended to include private colleges and universities with NCA designation in the program. After brief discussion and support from United Way Miami, the committee reported the bill favorably. Finally, CS/HB 177 was introduced as a framework for Florida’s regional councils to cross-assign bills among regions; it received supportive testimony and was also reported favorably. The meeting then adjourned.

Transcript Highlights:

• The FDA sent out warnings a year ago about counterfeit Botox in multiple states resulting in hospitalizations
• The FDA sent out warnings, a year ago about counterfeit Botox in multiple states resulting in hospitalizations

Bills: SB213, SB378, SB610, SB681, SB918, SB1172, SB1252, SB1343, SCR8

Keywords: SB 213, Texas insurance, Insurance Code, Chapter 551, Chapter 541, bundling, tying arrangement, cross-selling, homeowners insurance, residential property insurance, auto insurance, personal automobile insurance, consumer protection, unfair trade practice, deceptive insurance practice, property and casualty insurer, Lloyd's plan, county mutual, reciprocal exchange, farm mutual

Summary: The Senate Committee on Business and Commerce met with a quorum and took up several pending bills, first reporting SB 1006 favorably after adopting a committee substitute that adds quarterly ZIP-code-level reporting to TDI on insurer declinations, cancellations, and nonrenewals. The committee also adopted substitutes and favorably reported SB 388, which adds nuclear to a credit program and excludes batteries from the dispatchable definition; SB 917; SB 504, which narrows reporting requirements for certain local entities, raises a salary threshold, and authorizes AG injunctive relief; SB 925, which clarifies that federal match dollars are included in a PLA-related prohibition; and SB 815, which removes downcoding references and focuses on AI use in prior authorization. SB 815 advanced on an 8-2 vote, while SB 388 advanced 6-3 and the others were reported 9-0 or 6-0 as noted. The committee then heard testimony on SB 378, which would prohibit aestheticians and cosmetologists from administering injections or using prescriptive medical devices unless legally authorized and would clarify TDLR disciplinary authority. The author and a retired neurosurgeon testified that unsafe, unauthorized injections pose real patient risks, and a TDLR witness said the bill addresses a long-standing regulatory gap. SB 378 was left pending after testimony. The committee also heard SB 1252, aimed at reducing municipal permitting barriers for residential backup power systems; the author and industry witnesses said city permitting is costly and inconsistent, while municipal utility representatives and advocates said the substitute preserved safety and utility oversight. That bill was also left pending. Additional bills heard but left pending included SB 1172, which would let LPs and LLCs sell their own property without a real estate license; SB 681, which would extend engineer license renewal periods and apply similar flexibility to engineering firms; SB 918, a TDLR cleanup bill for orthotics and prosthetics exemptions; SB 1343, which would require data brokers to post a clear link explaining Texans’ privacy rights and how to exercise them; SB 213, which would prohibit forced bundling of residential property and auto insurance while preserving voluntary discounts; SB 610, which would codify TDLR’s anti-trafficking unit; and SCR 8, expressing opposition to a central bank digital currency over privacy, security, and financial-stability concerns. Public testimony on SB 1343 and SB 213 was generally supportive, with consumer and advocacy groups emphasizing privacy, competition, and survivor safety, and the committee closed the day with those measures and others left pending.

Bills: SB2169, SB2263, SB2360, SB2359, SB2031, SB2796, SB3090, SB3091, SB3092, SB2120, SB2593, SB2751, SB2135, SB2024, SB2872, SB3179, SB2308, SB2392, SB2470, SB2398, SB2902, SB2841, SB2436, SB2806, SB2691, SB2824, SB2645, SB2384, SB2697, SB3153, SB3156, SB888, SB2423, SB2746

Keywords: business competitiveness, economic development, DBEDT, Department of Business Economic Development and Tourism, business climate, regulatory reform, permitting, economic ranking, state ranking, top 10 states, business climate improvement working group, business revitalization task force, CNBC America’s Top States for Business, Hawaii business climate, workforce development, infrastructure, cost of doing business, tax competitiveness, labor unions, private sector

Transcript Highlights:

• There in terms of the health impacts here, the FDA did a study of... ...they also just get littered and
• In terms of the health impacts here, the FDA did a study of...
• In terms of the health impacts here, the FDA did a study of polystyrene containers and found that most

Keywords: 995, all

Summary: The Senate took up a major environmental bond bill with amendments covering climate resilience, housing health, plastics reduction, coastal protection, fisheries, and related regulatory issues. Early debate included Senator Keenan’s withdrawn amendment to fund the Massachusetts Healthy Homes Program with $50 million, followed by his adopted amendment banning hotels from providing plastic toiletry packages. Senator Tarr’s amendment to remove the paper bag charge was defeated after extended debate over whether the 10-cent bag assessment functioned as a tax; a related floor speech from Senator Duner argued the fee would burden working families. The chamber also adopted Senator Fernandez’s ocean acidification amendment, which would aggregate ocean monitoring data to support shellfish, water quality, and coastal management, with support from Senators Sear and Driscoll. Other adopted measures included Driscoll’s Houghton’s Pond multi-use trail, Montigny’s New Bedford State Pier redevelopment and harbor oil-recovery provisions, Collins’s Commonwealth Conservation Commission later withdrawn, and several coastal resilience and housing-related amendments. The Senate also approved a series of environmental and public health measures. Senator Moore’s rodenticide restriction amendment was adopted after testimony from animal welfare and conservation groups, with the sponsor describing harms to wildlife, pets, and livestock and noting local municipal support. Senator Lewis’s amendment directing DEP to study the feasibility of banning polystyrene was adopted, as was Senator Mark’s Massachusetts Climate Bank amendment and Senator Edwards’s carbon sequestration amendment expanding attention to salt marshes, seagrasses, and waterways. The chamber adopted amendments on equitable representation, improving indoor air quality, and a Douglas State Forest trust fund that would raise the entry fee from $1 to $2 for maintenance. Several amendments were withdrawn, including Collins’s urban coastal resilience commission and Tarr’s proposed Commonwealth Conservation Commission. Housing and permitting issues were another major theme. Senator Driscoll’s amendment requiring local confirmation before a project is designated a priority housing project was defeated, but his related amendments clarifying the process and requiring consultation with the Housing and Livable Communities Secretary were adopted. The Senate also adopted Crichton’s amendments streamlining permitting for coastal resiliency projects in urban areas and creating a five-year pilot for nature-based solutions, as well as Tarr’s amendment adding dredging and sand placement to general coastal permits. Tarr’s amendment to revise the Salisbury Beach Preservation Trust Fund was adopted, while his later constitutional challenge to a landform-migration provision was withdrawn after he argued it could amount to an uncompensated taking. The session ended with the Senate noting only two amendments remained and then adjourning in memory of Quincy’s former mayor James A. Sheets.

Transcript Highlights:

• the cacophony of uncertainty at the federal level, whether it's tariffs or pricing, NIH funding, or FDA
• NIH funding or FDA cuts has led us to this third year of a biotech winter that we're currently in.
• In the rare case that we see new discoveries and therapies get across the FDA finish line, when we do

Summary: The Assembly Select Committee on Biotechnology and Medical Technology met on August 19, 2025 to examine the effects of federal grant cuts, tariff uncertainty, and related policy changes on California’s biotech, medtech, and academic research ecosystem. The chair and panelists emphasized California’s outsized role in the industry, describing major clusters in the Bay Area, Los Angeles, and San Diego, and explaining how research, startup formation, manufacturing, and clinical trials are interconnected across the state. Speakers from Biocom California, California Life Sciences, Farma, UC, Stanford, CSU Biotech, and UCLA all argued that NIH and NSF funding are foundational to discovery, workforce training, and commercialization, and that disruptions are already chilling venture capital, startup formation, and hiring. Witnesses described several concrete impacts: suspended or terminated grants, reduced doctoral admissions, fewer training opportunities, canceled retreats and internships, and anxiety among graduate students and early-career researchers. UC reported hundreds of millions of dollars in suspended or terminated NIH and NSF funding, while Stanford said more than a thousand training and career-development grants nationwide have been frozen or ended, affecting multiple trainees per grant. CSU Biotech said 133 federal grants had been terminated, scaled back, or canceled, totaling about $140 million, including nearly $30 million from NIH and NSF. Industry representatives also warned that proposed antitrust limits on mergers and acquisitions could undermine the standard biotech exit path and further deter investment. Committee members asked about the duration of the disruption, the possibility of state action to offset federal losses, and whether California could better support workforce development, manufacturing, and R&D tax credits. Panelists urged the Legislature to preserve and expand state support for STEM education, internships, apprenticeship pathways, manufacturing incentives, and the R&D tax credit, and to consider infrastructure and housing as part of competitiveness. They also noted that tariffs are already raising costs for medtech components and building materials, and that China is increasingly competing for R&D, talent, and licensing deals. No formal votes or bill actions were taken at the hearing; the meeting was informational and focused on testimony and discussion.

Transcript Highlights:

• Industry will say that the FDA says these chemicals are safe.
• However, the FDA has been asleep at the wheel on many critical public health issues, and in the case
• However, the FDA has been asleep at the wheel on many critical public health issues, and in the case

Summary: The committee heard several environmental and consumer-safety bills. AB 405, the Fashion Act, would require fashion companies to disclose and manage toxic chemicals in their supply chains; supporters said it would reduce worker and consumer exposure and align with existing industry frameworks, while retailers and business groups argued it would duplicate existing laws and raise costs. After questions about DTSC workload, international standards, and affordability, the bill was moved on a due-pass-as-amended motion to Natural Resources and held on call with three votes. AB 762 would ban the sale and distribution of disposable vape devices; supporters emphasized battery-fire risks, recycling contamination, and waste impacts, while cannabis and convenience-store interests warned it would push consumers to illicit markets and harm legal businesses. The bill passed on a due-pass motion to Business and Professions with three votes and was held on call. The committee also adopted the consent calendar with six votes. AB 794 would direct California to keep in place the federal PFAS drinking-water standard if federal protections are weakened, with supporters citing health risks and the need for certainty, and water agencies opposing the emergency-rulemaking authority and potential costs. Members debated whether the bill was too broad and whether federal funds would cover implementation; the bill passed on a due-pass-as-amended motion to Appropriations with four votes and was held open. AB 1148, the Safer Food Packaging Act, would restrict certain chemicals in food packaging; supporters cited cancer and reproductive-health concerns, while chemical, beverage, and manufacturing groups argued the bill should go through existing regulatory processes and that some chemicals lacked feasible alternatives. The author said she would remove antimony trioxide later in the process after hearing opposition concerns; the bill passed on a due-pass motion to Judiciary with four votes and was held open. Finally, AB 1338 would allow local air districts to recover costs for implementing fence-line air monitoring at metal shredding facilities, building on prior legislation and local air district efforts in AB 617 communities. The author said the bill would preserve local control and improve efficiency, and the South Coast Air Quality Management District testified in support. The transcript ends as the district witness begins testimony, with no vote yet taken on AB 1338.

Transcript Highlights:

• all processed Charlotte's Web, which are all processed at<00:33:49.519> an<00:33:49.679> FDA
• regulated facility, every item at an FDA regulated facility, every item is<00:33:51.919> tested
• It's so confusing. >> Has it been left up to the DEA or the FDA?
• the >> Has it been left up to the DEA or the >> Has it been left up to the DEA or the FDA
• <01:02:24.640> I<01:02:24.720> mean, FDA? I mean, FDA?

Keywords: 1189, house, all

Transcript Highlights:

• As of today, only 39 e-cigarette products have marketing granted orders, and the FDA has clearly stated
• As of today, only 39 e-cigarette products have marketing granted orders, and the FDA has clearly stated
• get these out of our hands, especially our keiki, who are being targeted by these products that the FDA
• ,<00:10:21.040> over<00:10:21.440> 6,800 products um by the FDA, over 6,800 products
• um by the FDA, over 6,800 products<00:10:22.560> remain<00:10:22.880> on<00:10:23.040>

Keywords: 912, senate, all

Summary: The committee heard testimony on several health-related measures, with most of the discussion focused on bills addressing tobacco/vape enforcement, psychology licensure, hospital price transparency, prior authorization, and medical cannabis. The chair opened by explaining the one-minute testimony limit and that written testimony had been reviewed. For SB 2175 on disposable electronic smoking devices, the Department of Health said the bill’s placement in litter-control law was not a good fit because disposable e-cigarettes contain hazardous materials like lithium and nicotine, but it supported the intent and pointed to a related measure. Public health and tobacco-control advocates strongly supported the bill, citing youth use, toxic waste, battery fires, and the need to tighten definitions and remove exemptions; a long list of organizations and individuals were noted in support, with no opposition mentioned. For SB 2410, which would create a state directory and enforcement tools for authorized e-cigarette products, the Attorney General’s office strongly supported the measure and said it would help enforce the FDA-authorized list of products through certification, inspections, and civil penalties. The Department of Health said thousands of illegal products remain on the market and cited youth usage rates, while public health groups also supported the bill. One tobacco industry-related witness was noted in opposition. SB 2080, the psychology interjurisdictional compact, drew support from the Department of Corrections, which said it had severe staffing shortages and that the compact would help fill gaps, especially for forensic psychology and neighbor island facilities. Some committee members raised concerns about whether the compact would loosen licensure standards and reduce licensing revenue, and the Board of Psychology was said to be meeting and had not taken a formal position; testimony also noted the need for resources if the compact were adopted. The committee also heard SB 2276 on surgical assistance, with DCCA in opposition and a supporter from the field, but little discussion followed. SB 2277 on hospital price transparency drew support from consumer and patient advocates, who argued that clearer pricing would reduce medical debt and help patients shop for care; DCCA and the Department of Health offered comments, with the department suggesting an alternative enforcement model using outside review entities and noting that implementation would require significant staffing and funding. The Healthcare Association of Hawaii opposed the bill, saying federal transparency rules already cover the issue and state law could create duplication. SB 2282 on prior authorization received comments from insurers and providers; HMSA asked that the bill be set aside pending the report of the prior authorization working group created by Act 151, while the Hawaii Medical Association said prior authorization is a major burden but deferred to regulators on resources. Finally, SB 2413 on medical cannabis was supported by the Office of Medical Cannabis and others, who said the bill would close a patient-access gap by allowing viable seed sales; one witness suggested clarifying jurisdictional language and allowing dispensaries to sell seeds to each other. The committee then began SB 2425 on health insurance, where an addiction treatment provider testified that insurers’ refusal to honor assignment-of-benefits payments can delay reimbursement and create relapse risk for patients, but the transcript cuts off before further action on that bill.

Transcript Highlights:

• products like that have shown low levels of extractable lead and cadmium and are in compliance with FDA
• <01:35:38.960> Testing<01:35:39.280> of the FDA requirements.
• Testing of the FDA requirements.
• <01:35:50.000> in<01:35:50.320> compliance<01:35:50.800> with<01:35:51.120> FDA
• cadmium and are in compliance with FDA cadmium and are in compliance with FDA requirements. requirements

Keywords: 1183, house

Transcript Highlights:

• Making this therapy available here in Minnesota wasn't easy, but it was the catalyst for FDA approval
• was<00:10:15.760> the<00:10:16.000> catalyst<00:10:16.480> for<00:10:16.640> FDA
• ><00:10:17.200> approval<00:10:17.839> of<00:10:18.079> a was the catalyst for FDA
• Initially, labs can add MLDD as a laboratory-developed test, and an FDA-approved MLDD newborn screening
• laboratory developed test and an FDA laboratory developed test and an FDA approved<00:13:15.839>

Keywords: 1187, senate, all

Transcript Highlights:

• <00:04:47.039> Control<00:04:47.560> agency<00:04:48.520> and<00:04:49.000> FDA
• Control agency and FDA and our organization<00:04:51.440> have<00:04:51.680> tested<00
• FDA did an investigation on larger retailers, and they found that many of these retailers were selling
• FDA did an investigation on larger retailers, and they found that many of these retailers were selling
• FDA did an investigation on larger retailers, and they found that many of these retailers were selling

Keywords: 1187, senate, all

Transcript Highlights:

• <03:25:01.600> and including advertisements to the FDA and including advertisements to the
• FDA and other<03:25:02.239> regulatory<03:25:02.960> agencies.
• The FDA<03:26:21.359> has<03:26:21.520> a<03:26:21.680> function<03:26:22.000>
• You<03:27:41.600> said<03:27:41.760> that<03:27:42.000> the<03:27:42.160> FDA
• truckloads of information and the uh FDA truckloads of information and the uh FDA has<03:28:05.600

Keywords: 1189, house, all

Transcript Highlights:

• And so the Tobacco Control Act granted the FDA the power to regulate these e-cigarettes.
• the power to regulate granted the FDA the power to regulate these<02:56:35.279> ecigarettes.
• <02:56:38.640> 39<02:56:39.439> ecigarette FDA has only authorized 39 ecigarette FDA
• <02:57:35.200> has in locks step with what the FDA has in locks step with what the FDA has
• the reason for that is because the FDA the reason for that is because the FDA has<03:01:48.720><

Keywords: 910, house, all

Summary: The House Committee on Judiciary and Hawaiian Affairs heard testimony on two immigration-enforcement bills: HB 1886 HD1 and HB 2540 HD1. HB 1886 would limit state and federal collaboration in immigration enforcement, require visible identification and restrictions on facial coverings for law enforcement officers, and create offenses for improper masking, lack of identification, and unauthorized civil immigration interrogation, arrest, or detention. HB 2540 would also limit state and federal collaboration, require law enforcement agencies to adopt and publicly post written civil immigration enforcement policies, prohibit stops or arrests based solely on immigration status, and restrict state and county participation in civil immigration enforcement in certain places. Most testimony supported both measures. The Office of Hawaiian Affairs, the Office of the Public Defender, the ACLU of Hawaii, the Hawaii Coalition for Immigrant Rights, the Legal Clinic, and several private individuals said the bills would increase transparency, accountability, and community trust, and would help protect constitutional rights and reduce fear among immigrants and other community members. Several testifiers emphasized Hawaii’s history and the need to keep local law enforcement separate from federal immigration enforcement, while others said the bills would help people feel safer going to court, school, work, or public protests. A retired police officer also supported visible identification and uniform standards for officers, including federal agents operating in Hawaii. A few testifiers opposed the use of masked or unidentified officers and argued that local police should not be diverted from ordinary public safety duties to immigration enforcement. One ACLU witness noted that the federal government has increasingly used local and state agencies to expand immigration enforcement, and said the task-force provisions in the bills are important to prevent blurred lines between agencies. The committee did not take a final vote in the portion of the meeting provided, but it recorded very large numbers of supportive testimonies for both bills, with only a small number in opposition.

Transcript Highlights:

• This is part of the reason that in 2022, the FDA authorized the distribution of over-the-counter hearing
• This is part of the reason that in 2022, the FDA authorized the distribution of over-the-counter hearing

Summary: The Committee on Commerce and Tourism met with a quorum present and considered several bills. It first took up SB 232 on debt collection, where the sponsor explained a strike-all amendment and the committee adopted a Gruters amendment clarifying that email communications may be sent at any hour while other off-hours communications remain restricted. Testimony was sharply divided on a proposed change from “any person” to “debt collector,” with consumer advocates, legal aid, and the Florida Justice Association warning it would narrow Florida’s consumer protections, while supporters said the bill and amendment would address ambiguity affecting businesses. After debate, the committee rejected the broader amendment, adopted the email-only clarification, and reported CS for SB 232 favorably by roll call vote. The committee then heard and unanimously reported favorably CS for SB 126, which would allow prescription hearing aids to be sold and distributed by mail after a Florida-licensed audiologist or hearing aid specialist conducts the required examination, including remotely through telehealth. Supporters said the bill would improve access and reduce barriers for seniors and others with hearing loss, and no opposition was heard. The committee also heard SB 600 and SB 602 on manufacturing, which would create and fund a statewide Office of Manufacturing, a promotional campaign, workforce grants, and related fees; multiple industry and economic development groups appeared in support, and both bills were reported favorably. Next, the committee considered CS for SB 92 on hit-and-run accountability in vehicle repair shops. The sponsor described the bill as a response to rising hit-and-run incidents and explained that repair shops would have to complete a transaction form or retain a crash report for certain repairs, with a clarifying amendment adopted without objection. Prosecutors and law enforcement supporters said the bill would help identify offenders, while auto dealer representatives argued it could impose burdens and penalties on repair shops. The committee nevertheless reported CS for SB 92 favorably. Finally, the committee heard SB 412, the Motorized Wheelchair Right to Repair Act, which would require manufacturers to provide repair manuals, diagnostic tools, and parts to owners and independent repair providers under fair and reasonable terms. Disability advocates and wheelchair users testified that repair delays can leave users stranded for weeks or months, and the committee reported the bill favorably by roll call vote before adjourning.

Transcript Highlights:

• The ones that have cleared the FDA and these have actually been in the background and being worked on
• The where it has cleared the FDA<01:18:16.640> and<01:18:16.800> these<01:18:17.040>
• :17.280> actually<01:18:17.840> been<01:18:18.080> in<01:18:18.320> the FDA
• and these have actually been in the FDA and these have actually been in the background<01:18:18.880>
• The ADA supports comprehensive coverage for obesity treatments, which include access to FDA-approved

Keywords: 1189, house, all

Transcript Highlights:

• which are FDA approved and HIPPA<05:38:18.958> compliant<05:38:19.520> and<05:38:19.920
• and are HIPAA compliant, because that's it's been through the scrutiny of the FDA and the HIPAA law,
• <05:43:22.878> Um by the FDA and are HIPPA compliant.
• Um by the FDA and are HIPPA compliant.
• and the HIPPO law scrutiny of the FDA and the HIPPO law and<05:43:29.280> you<05:43:29.520>

Keywords: 1191, senate, all

Transcript Highlights:

• some very good reasons, but almost every one of those products has been canceled by the EPA or the FDA
• We have the isoxazoline products that are now gaining registrations by FDA, which has been very, and
• We fall under FDA and EPA, two very different federal agencies, and what a veterinarian is allowed to
• use off-label falls typically under FDA, whereas EPA is more strict in what can and can't be used.
• Whether it’s EPA, FDA, Department of War, or USDA, we’re able to make it go much faster than historically

Keywords: 1185, senate, all